As of the latest Form 4 filed Jun 23, 2026.
What Allogene Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 14 most recent filings for ALLO.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-23 | 2026-06-18 | Kazam Joshua A Director | MExercise | +47.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-23 | 2026-04-21 | Yoshiyama Annie SVP, Finance | SSale | −9.59K | $2.31 | $22.1K | No | Form 4 ↗ |
| 2026-04-02 | 2026-03-31 | Beneski Benjamin Machinas SVP, Chief Technical Officer | SSale | −2.87K | $2.50 | $7.17K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Beneski Benjamin Machinas SVP, Chief Technical Officer | SSale | −4.83K | $2.47 | $11.9K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Chang David D President and CEO | SSale | −47.8K | $2.47 | $118K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | SSale | −7.13K | $2.60 | $18.5K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | SSale | −7.55K | $1.73 | $13.1K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Chang David D President and CEO | SSale | −95.3K | $1.80 | $171K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | SSale | −24.0K | $1.76 | $42.2K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Yoshiyama Annie SVP, Finance | SSale | −4.17K | $1.72 | $7.17K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Roberts Zachary EVP of R&D | SSale | −35.7K | $1.77 | $63.2K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Douglas Earl Martin SVP, General Counsel | SSale | −22.9K | $1.76 | $40.3K | No | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Roberts Zachary EVP of R&D | SSale | −26.3K | $1.56 | $41.0K | No | Form 4 ↗ |
| 2025-12-22 | 2025-12-18 | Kazam Joshua A Director | MExercise | +47.7K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ALLO’s full analysis or the market-wide insider trading feed. The tabs above jump to ALLO’s other SEC data.
Source: SEC Form 4 filings for ALLO, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.